HMB Supplement for Alcoholic Liver Disease and COVID-19
Study of HMB-enriched Amino Acid Supplementation in Patients With Alcoholic Liver Disease and COVID-19
Recruiting
N/A
Interventional Study
Alcoholic Liver Disease
COVID 19 Pneumonia
At a Glance
- Age
- 21 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Basic Science
- Participants needed
- 48 (estimated)
- Sponsor
- The Cleveland Clinic · Other
Who this trial is looking for
This trial is looking for patients who have both alcoholic liver disease and COVID-19 pneumonia. Participants will receive a supplement called HMB to see if it helps improve their condition and recovery.
Are You a Good Fit for This Trial?
You may be able to join if
- I have been diagnosed with alcoholic cirrhosis or alcoholic hepatitis.
- I have a Child Pugh score between 5 and 8.
- I have been diagnosed with COVID-19 pneumonia.
- I am 21 years or older.
You may not be able to join if
- I require active ventilator support.
- I have had recent gastrointestinal bleeding.
- I have advanced organ diseases like heart failure or severe COPD.
- I am pregnant.
- I am unable to sign informed consent.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your Eligibility
About This Trial
Patients with COVID-19 and comorbidities including alcohol associated liver disease (ALD) are at risk for severe illness and abrupt or sudden clinical deterioration with ventilatory failure. â-hydroxy â-methyl butyrate (HMB), a non-nitrogenous leucine metabolite with anabolic properties, increases muscle mass and contractile function and enhances immune function. We aim to study the natural course…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
A. Cases: Patients with ALD and COVID-19 pneumonia:
1. Clinical, imaging, laboratory, and/or histological diagnosis of alcoholic cirrhosis and/or alcoholic hepatitis
2. Child Pugh score 5-8, serum creatinine \<3, Model for End Stage Liver Disease score (MELD) \<25
3. Diagnosis …
Contacts